Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer

Mostrar otras versiones (1)

Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal hormone-receptor-positive breast cancer. Previous studies have shown that there is no cross-resistance between exemestane and reversible aromatase inhibitors. Exposure to hormonal therapy does not hampe...

Descripción completa

Detalles Bibliográficos
Autores principales: Iaffaioli, R V, Formato, R, Tortoriello, A, Prete, S Del, Caraglia, M, Pappagallo, G, Pisano, A, Fanelli, F, Ianniello, G, Cigolari, S, Pizza, C, Marano, O, Pezzella, G, Pedicini, T, Febbraro, A, Incoronato, P, Manzione, L, Ferrari, E, Marzano, N, Quattrin, S, Pisconti, S, Nasti, G, Giotta, G, Colucci, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362023/
https://www.ncbi.nlm.nih.gov/pubmed/15856035
http://dx.doi.org/10.1038/sj.bjc.6602579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362023/
https://www.ncbi.nlm.nih.gov/pubmed/15856035
http://dx.doi.org/10.1038/sj.bjc.6602579

Ejemplares similares